![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 36, 25807-25813, September 3, 1999
From the Department of Biological Chemistry and Molecular
Pharmacology, Harvard Medical School, Boston, Massachusetts 02115
Mutation of glutamate 62 to lysine in yeast
transcription factor (TF) IIB (Sua7) causes a cold-sensitive phenotype.
This mutant also leads to preferential transcription of downstream
start sites on some promoters in vivo. To explore the
molecular nature of these phenotypes, the TFIIB E62K mutant was
characterized in vitro. The mutant interacts with
TATA-binding protein normally. In three different assays, the mutant
can also interact with RNA polymerase II and recruit it and the other
basal transcription factors to a promoter. Despite the ability to
assemble a transcription complex, the TFIIB E62K protein is severely
defective in transcription in vitro. Therefore, the role of
TFIIB must be more than simply bridging TATA-binding protein and
polymerase at the promoter. We propose that the region around Glu-62 in
yeast TFIIB plays a role in start site selection, perhaps mediating a
conformational change in the polymerase or the DNA during the search
for initiation sites. This step may be related to the yeast-specific
spacing between TATA elements and start sites since mutations of the
corresponding glutamate in mammalian TFIIB do not produce a similar effect.
Transcription initiation by RNA polymerase II (pol
II)1 in eukaryotes requires
an assembly of general transcription factors on the promoter to form a
preinitiation complex (PIC) (reviewed in Refs. 1-3). An initial
committed complex is formed by TBP/TFIID binding to the TATA element of
a promoter (4). Subsequent interaction with TFIIB bridges TFIID on the
TATA element and RNA pol II/TFIIF, TFIIE, and TFIIH (5). Several steps
occur after transcription complex assembly, including promoter melting,
start site selection and initiation, promoter clearance, elongation,
and reinitiation. During the initiation process, numerous
protein-protein and protein-DNA interactions must be established,
adjusted, and then disrupted as the transcription machinery moves away
from the start site.
The mechanism of transcription start site selection is not well
characterized. In higher eukaryotes, promoter melting and transcription
initiation overlap at a fixed distance of ~25 nucleotides downstream
from a TATA box (6, 7), suggesting that start site selection is simply
due to the geometry of the transcription complex. In contrast,
initiation in Saccharomyces cerevisiae generally occurs at
multiple sites within a broad window of 30-120 nucleotides from TATA
(8-11).
Genetic methods have been applied to identify factors that affect start
site selection in yeast cells. Mutations in TBP (spt15 alleles (12)), TFIIB (sua7 (13)), and two polymerase
subunits (rpb1/sua8 (14) and rpb9/shi/ssu73
(15-18)) can alter start site selection in vivo. In
contrast to the spt mutations, which affect TATA element
selection, the sua and shi mutations alter the
spacing between the TATA element and initiation sites. Rather than
causing completely novel initiation sites to be used, the mutations
change the relative usage of normal initiation sites (i.e.
strongly favoring upstream or downstream start sites). It is
interesting to note that these mutations generally do not affect
overall promoter strength and that many promoters are unaffected. In
agreement with the genetic experiments, species-specific selection of
transcription start sites in S. cerevisiae and
Schizosaccharomyces pombe was specified in vitro
by pairwise replacement of both TFIIB and pol II (19).
TFIIB has two domains that correlate with its two known interactions.
At the N terminus is a zinc ribbon domain that is essential for the pol
II/TFIIF recruiting activity (20, 21). A proteolytically resistant
C-terminal domain of TFIIB is necessary and sufficient for the
interaction with the TBP·DNA complex (20-24). The structures of
these two domains have been characterized separately (25-27). However,
a highly conserved region linking two domains does not appear in the
structures and has been proposed to be a flexible "hinge" region.
Although the N-terminal domain of TFIIB is absent from the x-ray
structure of the DNA·TBP·TFIIBc complex, this domain is predicted
to be close to the initiation site (27).
TFIIB physically links TBP/TFIID and pol II/TFIIF and may thereby
define the spacing between them. Some mutations in the TFIIB hinge
region can dramatically affect the spacing between the TATA element and
the initiation sites in vivo (13, 28, 29). This phenotype
allowed the original isolation of the yeast TFIIB gene (SUA7) as a suppressor of upstream
ATG codons (13). Interestingly, these start site selection
mutants also exhibit a cold-sensitive phenotype. In an attempt to
characterize the role of TFIIB in transcription start site selection,
we analyzed one of the Sua7 mutant proteins in vitro.
Surprisingly, we found that the Sua7 E62K mutant can assemble
transcription complexes normally, but is severely defective in
transcription in vitro. These findings indicate that TFIIB
is required not only for initial assembly of the transcription complex,
but also for a later step in initiation such as promoter melting, start
site selection, or promoter clearance.
Native Protein Purification--
The purification of RNA pol II
and TFIIH was described (30). The Mono S (HR 5/5) (Amersham Pharmacia
Biotech) fractions obtained during the purification of TFIIH (30) were
used for the purification of TFIIF. The fractions were assayed by
immunoblot analysis using anti-Tfg2 polyclonal antibody. The TFIIF
fractions were pooled and applied directly onto a Mono Q (HR 5/5)
column (Amersham Pharmacia Biotech) pre-equilibrated with buffer A (20 mM HEPES-KOH (pH 7.6), 1 mM EDTA, 1 mM DTT, and 20% (v/v) glycerol) containing 0.5 M KOAc and protease inhibitors (1 µg/ml antipain, 2 µg/ml aprotinin, 0.1 mM benzamidine HCl, 5 µg/ml
chymostatin, 1 µg/ml pepstatin A, 0.5 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride). The column was developed
with a 15-ml gradient of 0.5-1 M KOAc in the same buffer.
Fractions containing TFIIF, which eluted at ~0.85 M KOAc,
were pooled and dialyzed against storage buffer (20 mM
HEPES-KOH (pH 7.6), 0.1 M KOAc, 1 mM EDTA, 1 mM DTT, 50% (v/v) glycerol, and protease inhibitors).
Recombinant Protein Production and Purification--
The open
reading frames of wild-type and E62K, G204D, and C45F mutant Sua7 genes
were amplified by polymerase chain reaction; cloned into pET-11d; and
transformed into Escherichia coli BL21(DE3)/pLysS. The
C-terminal truncation expression construct (Met-119 to the end) was
generously provided by Song Tan (Pennsylvania State University). Each
strain containing wild-type or mutant plasmid was cultured in LB medium
supplemented with ampicillin (100 µg/ml) and chloramphenicol (34 µg/ml) at 30 °C. Cells were induced with
isopropyl- Co-immunoprecipitation of TFIIB and pol II--
200 ng of
recombinant yeast TFIIB (wild type or the indicated mutants) was
incubated with 400 ng of purified pol II in 200 µl of buffer A
containing 0.6 mg/ml bovine serum albumin and 0.03% Nonidet P-40 for
1 h at room temperature. The reaction mixture also contained 20 µl of protein A-Sepharose CL-4B beads (Amersham Pharmacia Biotech) to
preclear the reaction. After centrifugation to remove the beads, either
preimmune serum or anti-Sua7 serum (1 µl) and a fresh aliquot of
protein A-Sepharose beads were added to the reaction mixture.
Incubation continued for another hour at room temperature. The beads
were collected and washed five times with ice-cold buffer A plus 0.03%
Nonidet P-40 (1 ml each time). The precipitate was resuspended in 20 µl of SDS sample buffer and analyzed by SDS-polyacrylamide gel
electrophoresis and immunoblotting. Mouse monoclonal antibody 8WG16
against the C-terminal domain (CTD) of pol II (32) was used to detect
RNA pol II.
Gel Mobility Shift Assay--
The 10-13-µl binding reaction
mixture typically contained 20 mM HEPES-KOH (pH 7.6), 5 mM MgOAc, 30-60 µg/ml poly(dG·dC), 0.6 mg/ml bovine
serum albumin, 1 mM EDTA, 1 mM DTT, 10%
glycerol, and 1-3 × 104 cpm of probe. The
EcoRI/HindIII fragment of pRW, which contains the
adenovirus major late promoter TATA element and initiator, was used as
a probe (5). Protein components were added to the binding reaction as
indicated. The reaction mixture was incubated at room temperature for
30-50 min and loaded onto a 4% polyacrylamide gel containing 25 mM Tris, 40 mM glycine, and 1 mM
EDTA. Magnesium acetate (3 mM) was added to the gel in the
experiment shown in Fig. 3B. A typical binding reaction
contained 10 ng of TBP, 30 ng of TFIIB, 80 ng of pol II fraction, and
25 ng of TFIIF fraction.
In Vitro Transcription--
Whole cell extracts were prepared
from wild-type TFIIB cells (YSB143 = MATa,
ura3-52,
leu2-3,112, his3 Immobilized Template Assay--
Transcription template DNA was
made by cutting pGal4CG The TFIIB E62K Mutant Is Defective in Transcription in
Vitro--
The yeast TFIIB allele sua7-1
contains a substitution of lysine for glutamate 62 (E62K) and was
isolated as a suppressor of an aberrant ATG translation initiation site
in the leader region of the CYC1 gene (13). As a result of
this single amino acid substitution, transcription initiation sites at
some promoters are shifted downstream in vivo. In a search
for conditional alleles of SUA7, we independently isolated
E62K as a cold-sensitive
variant.2
To characterize the mechanism of transcription start site selection
in vitro, whole cell extract was prepared from yeast strains expressing either wild-type or E62K mutant TFIIB. The transcription template (pGal4CG
Transcription activity could be restored to the mutant extract by
addition of recombinant wild-type TFIIB (Fig. 1, lanes 6 and
7). However, addition of excess amounts of recombinant E62K protein to the mutant extract did not increase transcription levels, suggesting that the defect was not due to low levels of TFIIB protein
(Fig. 1, lanes 4 and 5). The recombinant E62K
protein also failed to support the transcription in a purified
reconstituted transcription system (data not shown). We also tested
several other promoters, including the adenovirus major late promoter (pML TFIIB E62K Can Interact with TBP and pol II to Form a Stable
DNA·TBP·TFIIB·pol II·TFIIF Complex--
Since E62K extracts
are defective in transcription, one or more essential interactions
within the transcription complex must be affected. TFIIB is known to
interact directly with TBP and with pol II. To characterize the
biochemical defect of E62K, two protein interaction assays were used:
co-immunoprecipitation with pol II and native gel electrophoresis of
partial transcription complexes. We also tested three additional mutant
proteins with well characterized defects. C45F mutant TFIIB is mutated
at a conserved cysteine residue within the zinc finger motif, and the "core" TFIIB is a complete deletion of this N-terminal domain. These mutants do not support viability in yeast (data not shown), and
similar substitutions in mammalian TFIIB block interaction with pol II
(20). Another mutant, G204D, causes a severe growth defect in yeast and
is severely defective in the interaction with TBP, consistent with
predictions from the DNA·TBP·TFIIB structure (27).
Co-immunoprecipitation experiments (Fig.
2A) showed that pol II could
bind to the wild-type and E62K and G204D mutant TFIIB proteins. In
contrast, the zinc finger mutant (C45F) and the N-terminal truncation
mutant (core) were not able to precipitate pol II, consistent with
other reports that the zinc finger region of TFIIB is necessary for pol
II interaction (20-24). The interaction between E62K and pol II was
not affected by lowering the temperature (Fig. 2B).
Therefore, the in vitro transcription defect and
cold-sensitive phenotype of E62K cannot be attributed to a defect in
pol II interaction.
We next used native gel electrophoresis to determine whether E62K and
the other mutant proteins were able to interact with TBP and to recruit
pol II and TFIIF to the promoter DNA. This system has previously been
used to analyze mammalian transcription complexes (5). With yeast
factors, complexes consisting of DNA·TBP·TFIIB (Fig.
3A) and
DNA·TBP·TFIIB·pol II·TFIIF (Fig. 3B) can be
visualized. All the TFIIB proteins except for G204D were able to form
the DNA·TBP·TFIIB complex, indicating that E62K is not defective in
this interaction (Fig. 3A). Formation of partial transcription complexes is visualized in Fig. 3B. In Fig.
3B, 3 mM magnesium acetate was included in the
gel and running buffer to destabilize nonspecific polymerase complexes.
The DNA·TBP·TFIIB complex was not seen under these conditions. Both
the wild-type and E62K mutant TFIIF proteins were able to form the
DNA·TBP·TFIIB·pol II·TFIIF complex (Fig. 3B). This
complex was completely dependent upon the presence of TFIIF. The TFIIB
mutant proteins defective in pol II interaction or TBP interaction were
unable to form a DNA·TBP·TFIIB·pol II·TFIIF complex on the
promoter. Therefore, the E62K mutant appears to be functional for
recruitment of pol II and TFIIF to the promoter DNA.
TFIIB E62K Effectively Assembles Transcription Initiation
Complexes--
The native gel electrophoresis assay allowed
observation of only partial transcription complexes, and therefore, it
was possible that the TFIIB mutant might block the association of other
transcription factors such as TFIIE or TFIIH. To look at complete
transcription complexes assembled from whole cell extracts, we took the
advantage of an immobilized template assay (30). Wild-type or mutant
extract was incubated with template DNA linked to magnetic beads. After incubation to allow transcription complexes to assemble, the beads were
collected magnetically and washed extensively. The presence of basal
transcription factors was assayed by immunoblotting, and
phosphorylation of the pol II CTD by TFIIH was detected by autoradiography (Fig. 4A).
Assembly of the transcription complex was dependent on the presence of
the promoter sequences (Fig. 4A, compare lanes 1 and 2) and was modestly stimulated by the presence of the
activator Gal4-VP16. Interestingly, the transcriptionally inactive E62K extract assembled all the required transcription factors at the promoter. Upon addition of ATP, the transcription complexes containing the TFIIB E62K mutant also exhibited phosphorylation of the Rpb1 CTD.
Therefore, the E62K mutant does not affect the ability of TFIIH to
phosphorylate the CTD.
To compare the immunoblot results with transcription activity,
complexes assembled on immobilized template beads were washed extensively and then incubated in a transcription reaction (Fig. 4B). To test for the ability of transcription factors to
exchange, a second template (pJJ460) was added along with the NTPs.
Transcription from wild-type complexes was dependent upon an intact
promoter and responded to the activator (Fig. 4B,
lanes 2-4). Transcription was from pre-assembled factors on
the immobilized template since no transcription was observed from the
second template (pJJ460) added after PIC formation. As previously
observed in the extracts, immobilized complexes assembled in the E62K
whole cell extract did not produce transcripts (Fig. 4B,
lane 6). Transcription from the mutant extract could be
rescued by addition of wild-type TFIIB, but only if the protein was
added before the beads were pelleted and washed (Fig. 4B,
compare lanes 7 and 8). Therefore, once assembled into the complete initiation complex, TFIIB and the other basal factors
cannot be exchanged freely.
E62K Transcription Is Defective in a Post-assembly Step--
In
some cases, multiple rounds of transcription initiation may occur from
a single template without the necessity of completely re-assembling the
PIC in each round. To determine whether TFIIB E62K might be normal for
the first round of transcription but defective in reinitiation, we
performed single round transcription reactions by blocking reinitiation
with the detergent Sarkosyl. Complexes were formed in the wild-type and
E62K extracts; NTPs were added to initiate transcription; and Sarkosyl
(0.1 or 0.3%) was added after 1.5 min of incubation. In the absence of
the Gal4-VP16 activator (Fig. 5,
odd-numbered lanes), the E62K extract was 5-10-fold less
active than the wild-type extract whether the reactions were single or
multiple rounds. Therefore, the E62K defect is manifested even during
the initial initiation event.
As shown in Fig. 5, Gal4-VP16 stimulated transcription under both
multiple (without Sarkosyl) and single (with Sarkosyl) round initiation
conditions. Under multiple round conditions, wild-type extracts showed
~6-fold activation, whereas E62K extracts showed ~2-fold
activation. Interestingly, the relative activation of transcription was
more strongly affected by Sarkosyl in wild-type extracts than in E62K
extracts. Wild-type extracts exhibited 2-fold activation when limited
to a single round of initiation, similar to E62K extracts under both
single and multiple round conditions. Gal4-VP16 is known to increase
reinitiation as well as PIC formation (41). Therefore, the E62K
extracts appear to carry out less Gal4-VP16-directed reinitiation than
the wild-type extracts. Although this observation might suggest that
E62K has a specific defect in reinitiation, it can also be explained by
the fact that E62K-containing complexes assembled in the first round
remain bound at the promoter and thereby inhibit reinitiation. The
second hypothesis is supported by the experiment in Fig. 4B.
In this reaction, where multiple reinitiations can occur, wild-type
TFIIB added back after PIC formation with E62K was not able to restore transcription.
Human Mutant Homologues Are Active for Transcription in
Vitro--
TFIIB is highly conserved over evolution, particularly in
the region C-terminal to the zinc finger region. In fact, it has been
shown that amino acids 52-140 of yeast TFIIB can be replaced by its
corresponding human sequences in vivo (42). Since sequence conservation over evolution suggests that this region has an important functional role in TFIIB, we wanted to know whether mutation of the
glutamate corresponding to Glu-62 would have similar effects on human
TFIIB. We therefore mutagenized glutamate 51 (corresponding to yeast
Glu-62) to alanine or arginine and expressed the mutants in E. coli along with human wild-type TFIIB. It has been shown that the
E62R mutant is phenotypically similar to E62K in yeast (28).
The transcription activities of human wild-type TFIIB and the Glu-51
mutants were compared in a reconstituted in vitro
transcription system (Fig. 6). In
contrast to results obtained with yeast TFIIB, both E51A and E51R were
unaffected in their ability to support in vitro
transcription. We also tested the proteins by native gel
electrophoresis and found that they were able to form a
DNA·TBP·TFIIB·pol II·TFIIF complex at levels similar to
wild-type TFIIB (data not shown). Therefore, the essential function
abrogated by the Glu-62 mutation in yeast TFIIB either is not
affected by the corresponding human Glu-51 mutation or is not
rate-limiting for mammalian transcription.
Although many aspects of pol II transcription are
conserved over eukaryotic evolution, spacing between the TATA element
and the initiation site is different in yeast. To understand start site
selection, we have begun to biochemically characterize a yeast TFIIB
mutant (E62K) that causes initiation to shift downstream relative to
wild-type transcription in vivo. In contrast to its in
vivo behavior, we find that the E62K mutation causes a profound loss of transcription activity in vitro. This defect is not
due to defects in TBP interaction since the E62K mutant TFIIB protein forms complexes as assayed by native gel electrophoresis. It is also
not due to a defect in pol II interaction as tested by three independent assays: co-immunoprecipitation of purified TFIIB and pol
II, native gel electrophoresis of a DNA·TBP·TFIIB·pol II·TFIIF complex, and assembly of initiation complexes on immobilized templates in crude extracts. The immobilized template experiment further demonstrated that each of the basal transcription factors is present in
the E62K mutant complexes. Therefore, we conclude that the E62K
mutation is likely to affect a step in transcription that occurs after
initiation complex assembly. We suspect that the step that is blocked
in vitro is also important for determining start site
selection in vivo.
What might this step be? Since a single TATA element can specify
multiple start sites in yeast, there must be some flexibility of
components between these two elements, i.e. in the
intervening DNA and/or the intervening proteins. One plausible model is
that after the transcription complex is assembled and DNA is unwound, the polymerase active site must be positioned within the newly formed
single-stranded region. Initiation sites would be recognized by
"scanning" the unwound DNA for the appropriate sequences (43, 44).
We suspect that movement in the TFIIB hinge region is required for this
step and is inhibited by the E62K mutation. A conformational change in
TFIIB would presumably require thermal energy, and the cold-sensitive
phenotype of the E62K strain might reflect an increase in the energetic
barrier in the mutant.
Several lines of evidence support a model in which TFIIB undergoes a
conformational change. 1) Regions of DNA melting on the yeast
GAL1 and GAL10 promoters were mapped in
vivo 20-80 bp downstream of the TATA element, well upstream of
the initiation sites (43). In higher eukaryotes, promoter melting and
transcription initiation overlap at ~25-30 bp from the TATA element
(45). Therefore, DNA melting and the start site selection step may be
closely coupled in higher eukaryotes, but in yeast, the polymerase may
be required to scan a larger region of unwound DNA before an initiation
site is chosen.
2) As estimated from two-dimensional crystallographic studies of yeast
pol II (44), the minimal distance from TFIIB (and presumably TBP/TATA)
to the active site of pol II is ~30 bp, consistent with the position
of the melted region mapped in vivo. A straight DNA path of
30 bp could explain the minimum distance from the TATA box to the start
site, but longer distances to the start site suggest alternative pathways.
3) In the presence of a transcriptional activator, mammalian TFIIB was
found to exhibit increased protease sensitivity. This sensitivity has
been interpreted as an indication of a conformational change.
Interestingly, the protease sensitivity maps near Glu-62 in the region
between the zinc finger and the repeats (46).
4) The cold-sensitive phenotype of a TFIIB E62G mutant is suppressed by
overexpression of the yeast PC4 homologue Sub1 (47). Furthermore, Sub1
becomes essential in the presence of this TFIIB mutant. The molecular
nature of these genetic interactions is not yet known. However, the PC4
protein is a transcriptional coactivator that binds melted regions of
DNA (48, 49). We speculate that increased Sub1 concentrations stabilize
an open transcription complex, allowing sufficient time for the TFIIB
conformation to occur in the mutant protein.
We note that several TFIIB mutants in residues close to Glu-62 have
been described (22, 29, 50) and exhibit several similarities to E62K.
Those tested are severely reduced for in vitro transcription
and cause start site alterations and/or cold sensitivity in
vivo. The R64E mutant is reported to stabilize binding of a
DNA·TBP·TFIIB complex, leading to the suggestion that this region
of TFIIB affects an interaction with DNA (29). Several of these mutants
(W63P, R64A, R64E, F66D, and H71E) have been shown to interact with pol
II by co-immunoprecipitation, although in the same set of experiments,
E62K did not (29, 50). We do not understand this discrepancy with our
results using E62K since our experiments suggest that E62K behaves very
similarly to other mutants at positions 63-66 (50). We also note that while this paper was being reviewed, findings similar to those in Fig.
4 were published for the TFIIB E62G mutant (51).
The proposed conformational change in yeast TFIIB may also be relevant
to the RNA polymerase III system, in which factor TFIIIB contains both
TBP and a TFIIB homologue. Kassavetis et al. (52) have
characterized certain mutant TFIIIB subunits (Brf or B") that can
recruit pol III, but that are inactive in promoter opening. We are
attempting to determine whether pol II transcription complexes with
TFIIB E62K are competent for promoter melting.
It is surprising that the human homologue of the E62K mutant appears to
function normally in transcription despite the high level of
conservation in this region. This indicates that the mutation probably
affects a step that is either specific to or rate-limiting only in the
S. cerevisiae transcription system. We presume that this
step is important for start site selection since yeast transcription
exhibits unusual and variable TATA-to-initiation site spacing and the
E62K mutation affects start site selection in vivo. While
this paper was being reviewed, another group also reported that human
Glu-51 mutant TFIIB transcribed the adenovirus major late promoter
normally (53). Interestingly, they also observed that the TFIIB mutant
showed an increase in downstream initiation sites on the adenovirus E4
promoter, which has multiple start sites. The downstream initiation
sites observed in vivo with the E62K mutant may represent
initiation events that are less dependent upon a TFIIB conformational
change, perhaps promoted by chromatin structure or some other aspect of
transcription that is not reproduced in the in vitro
systems. Further mechanistic and structural studies of TFIIB will help
to further define this step and help us to understand how the
transcription machinery determines initiation sites.
We thank Kate Dollard and Hong Zhou for the
original isolation and sequencing of the E62K mutant. We thank Song Tan
for the core TFIIB construct and Mike Hampsey for discussions.
*
This work was supported in part by National Institutes of
Health Grant GM46498 (to S. B.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
2
C. Dollard, H. Zhou, and S. Buratowski,
unpublished data.
The abbreviations used are:
pol II, polymerase
II;
PIC, preinitiation complex;
TBP, TATA-binding protein;
TF, transcription factor;
DTT, dithiothreitol;
CTD, C-terminal domain;
bp, base pair(s).
Evidence That Transcription Factor IIB Is Required for a
Post-assembly Step in Transcription Initiation*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-D-thiogalactopyranoside (0.4 mM)
when A600 nm reached 0.6. The preparation of
extract and the purification of each recombinant protein were performed essentially as described for human TFIIB by Buratowski and Zhou (20).
In the case of E62K and G204D, the full-length recombinant protein
fraction also contained a truncation product that arises from the
internal translation initiation at methionine 119 (31). To separate the
full-length protein from this product, the S-Sepharose (Amersham
Pharmacia Biotech) eluate fraction was applied to a hydroxylapatite
column (Bio-Rad) equilibrated with 10 mM potassium phosphate (pH 7.7), 100 mM KOAc, 1 mM DTT, 20%
glycerol, and 1 mM phenylmethylsulfonyl fluoride. Bound
proteins were eluted with a gradient to 240 mM potassium
phosphate in the same buffer. A second round of hydroxylapatite
chromatography was necessary for complete isolation of the full-length
protein. The final hydroxylapatite eluate was further purified by Mono
S (HR 5/5) fast protein liquid chromatography as described (20).
Proteins were monitored by Coomassie Blue staining and confirmed by
immunoblot analysis. Human wild-type and E51A and E51R mutant TFIIB
proteins were purified as described (20). Yeast TBP was expressed and
purified as described (20). The purification of Gal4-VP16 was described
(30).
200,
sua7
::LEU2 (pRS313-SUA7)) or
isogenic TFIIB E62K mutant cells (YSB176 = same genetic background
as YSB143 but containing (pRS313-sua7-35)) as
described by Woontner et al. (33). In vitro
transcription was performed as described by Woontner and Jaehning (34)
with slight modifications. Reaction mixtures (30 µl) contained 25 mM HEPES-KOH (pH 7.6), 10 mM MgOAc, 5 mM EGTA, 2.5 mM DTT, 100 mM KOAc,
8-10% (v/v) glycerol, 1 unit of creatine kinase (Sigma), 10 mM phosphocreatine (Sigma), 10 units of rRNasin (Promega), 4 mM phosphoenolpyruvate, 0.5 mM each CTP and
ATP, 10 µM UTP, 5 µCi of [
-32P]UTP
(3000 Ci/mmol; NEN Life Science Products), 0.5 mM
3'-O-methyl-GTP (Amersham Pharmacia Biotech), 60-80 µg of
whole cell extract protein, and 200 ng of pGal4CG
(35).
After a 50-60-min incubation at room temperature, reactions were
stopped and processed with RNase T1 and proteinase K as described (34).
For single round transcription, extracts were incubated with template
for 20 min in the transcription reaction buffer without NTPs to allow
formation of PIC. For multiple round initiations, the NTPs were added,
and the reaction mixture was further incubated for 20 min. For single
round transcriptions, Sarkosyl (0.1 or 0.3% final concentration) was
added 1.5 min after NTP addition and incubated for 10 min. The RNA was
extracted with phenol/chloroform, precipitated, and analyzed on a 7 M urea and 5% polyacrylamide gel. Reactions were
supplemented, where indicated, with 100 ng of Gal4-VP16. Mammalian
in vitro transcription was performed in a reconstituted
system as described by Buratowski and Zhou (20).
with EheI and
AflIII. The AflIII site was filled with
biotin-14-dATP (Life Technologies, Inc.), dGTP, dCTP, and dTTP using
Klenow fragment. Template DNA was then gel-purified. The 1.1-kilobase
pair fragment contains one Gal4-binding site, the CYC1
promoter, and a G-less cassette. The biotinylated fragment was
incubated with streptavidin-coupled M-280 Dynabeads (3-5 pmol of
DNA/mg of streptavidin-coupled M-280 Dynabeads; Dynal Inc.) in buffer B
(2 M NaCl, 10 mM Tris-Cl (pH 7.4), and 0.01%
Nonidet P-40) at room temperature overnight. As a promoterless negative
control, the EheI/AflIII fragment of
p(C2AT)19 (36) was used. The DNA-bound beads
were washed several times in buffer B and subsequently in Tris/EDTA
buffer. The beads were preincubated with bovine serum albumin (0.05 mg/ml) and washed briefly right before use with simple transcription
buffer (25 mM HEPES-KOH (pH 7.6), 10 mM MgOAc,
5 mM EGTA, 2.5 mM DTT, 100 mM KOAc,
and 10% glycerol). Transcription initiation complexes were assembled
on immobilized template DNA by incubation of 120 µg of whole cell
extract with 3 µl of beads in 60 µl of simple transcription buffer.
Hexokinase (2 units) and glucose (2 mM final concentration)
were added to the mixture during the assembly reaction to deplete
endogenous NTPs. After 40 min, the transcription complexes were
magnetically purified and extensively washed with simple transcription
buffer containing 0.003% Nonidet P-40. Beads were resuspended in
either SDS-polyacrylamide gel electrophoresis sample loading buffer
directly or kinase reaction buffer (37). The kinase reaction continued
for 1 h at room temperature. The reaction was stopped by addition
of sample loading buffer for SDS-polyacrylamide gel electrophoresis and
electrophoresed on a 4~20% gradient polyacrylamide gel (Bio-Rad).
The proteins were analyzed by immunoblotting with polyclonal antibodies
against TFIIB (anti-Sua7), TFIIE (anti-Tfa1), TFIID (anti-TBP), and
TFIIH (anti-Tfb1, provided by W. J. Feaver and R. D. Kornberg) and monoclonal antibody 8WG16. Autoradiography was used to
detect phosphorylated pol II.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
) contains a single Gal4-binding site
and the CYC1 TATA element upstream of a 400-bp G-less
cassette (35). In wild-type extracts, two major in vitro
transcription initiation sites are apparent (Fig.
1, lane 1). In contrast to its
in vivo behavior, E62K replacement greatly reduced in
vitro transcription activity at the CYC1 promoter (Fig.
1, lanes 2 and 3). The small amount of
transcription supported by E62K was still responsive to the activator
Gal4-VP16 (see below). PhosphorImager quantitation indicated that the
mutant extracts produced ~10-15-fold less transcript than the
wild-type extracts. Since the E62K mutant in vivo causes a
downstream shift in start site selection, the ratio of the two
transcripts was quantitated. Surprisingly, the ratio was roughly the
same in both extracts: ~1.5 downstream transcripts to each upstream
transcript.

View larger version (27K):
[in a new window]
Fig. 1.
The TFIIB E62K mutant is defective in
transcription in vitro. In vitro
transcription was performed with either wild-type (WT) or
E62K mutant TFIIB whole cell extracts in the presence (+) or absence
(
) of the activator Gal4-VP16. E62K transcription was supplemented
with 100 ng of either recombinant E62K (rE62K) (lanes
4 and 5) or recombinant wild-type (rWT)
(lanes 6 and 7) TFIIB. The two major transcripts
are indicated by arrows. The uppermost band
(indicated with an asterisk) is from read-through
transcription of the G-less cassette. The template plasmid used for the
transcription reaction (pGal4CG
) is shown at the bottom.
This plasmid contains a single Gal4-binding site and a CYC1
TATA element that controls expression of G-less transcripts 350-370
nucleotides long.
53(200) (38)), the IgH promoter (pµ(
47)-G
-IV
(39)), the IgH-adenovirus major late hybrid promoter
(pµ(-47)-ML-(G
) (40)), the PYK1 promoter
(pPYKC/G
; gift from R. D. Kornberg), and
his4-912
(pLG80; gift from F. Winston). None of them were
transcribed efficiently in the E62K mutant extract (data not shown).
Based on these findings, we conclude that the TFIIB E62K mutant protein
is intrinsically defective in at least one function required for normal transcription.

View larger version (35K):
[in a new window]
Fig. 2.
TFIIB E62K can interact with RNA polymerase
II. A, recombinant wild-type (WT) or several
mutant TFIIB proteins were incubated with purified pol II for 1 h.
The reactions were immunoprecipitated with anti-Sua7 (yeast TFIIB)
antibodies. The precipitates were then immunoblotted with antibodies
against the largest subunit of pol II (8WG16). B,
interaction of wild-type and E62K mutant TFIIB proteins with pol II was
examined at both 4 and 25 °C. The binding reaction and precipitation
were performed as described for A. Reactions incubated at
the indicated temperatures were precipitated with either antibodies
against TFIIB (anti-Sua7) or preimmune serum (PIS).

View larger version (58K):
[in a new window]
Fig. 3.
TFIIB E62K can interact with TBP and pol
II/TFIIF to form a transcription complex on the promoter.
A, the ability of each TFIIB to interact with TBP bound to
the promoter was tested by native gel electrophoresis. Two different
amounts (20 and 40 ng) of each TFIIB or no TFIIB (designated
) was
incubated with TBP (10 ng) and the adenovirus major late promoter DNA
probe for 30 min at room temperature. The DNA·TBP·TFIIB
(DB) complexes were resolved on the native gel.
B, different combinations of general transcription factors,
as indicated at the top, were incubated at room temperature for 40 min.
The complexes were resolved on the native gel containing 3 mM MgOAc. The promoter complexes formed on the promoter DNA
probe are denoted as follows: D, DNA·TBP; and
DBPolF, DNA·TBP·TFIIB·pol II·TFIIF (also marked by
an asterisk).

View larger version (28K):
[in a new window]
Fig. 4.
TFIIB E62K can recruit the basal
transcription factors to form a transcription complex on the
promoter. A, transcription complexes were assembled on
beads carrying either a DNA fragment containing the CYC1
promoter (lanes 2-5) or a control fragment without a
promoter (lane 1). Extracts were from either wild-type
(WT) or E62K mutant TFIIB cells. The activator Gal4-VP16 was
added as indicated. The immobilized templates were washed extensively,
collected, and tested for the presence of various transcription factors
by immunoblotting. Rpb1 is the largest subunit of pol II; Tfb1 is a
subunit of TFIIH; Tfa1 is a subunit of TFIIE; Tfg2 is a subunit of
TFIIF; Sua7 is TFIIB; and TBP is the TATA-binding protein subunit of
TFIID. Before gel electrophoresis, the beads were incubated with
[
-32P]ATP, and the phosphorylated CTD of Rpb1
(Rpb1 (*P)) was detected by autoradiography (bottom
panel). B, E62K is stably incorporated into the
transcription complex. The yeast whole cell extracts were incubated
with immobilized template beads carrying a promoterless (lane
2) or CYC1 promoter-containing (lanes 3-8)
template. Transcription complexes were purified as described for
A, except that 80 ng of recombinant wild-type
(rWT) TFIIB was added before (lane 7) or after
(lane 8) complex purification. The washed beads were
resuspended in transcription buffer that also contained 300 ng of
pJJ460. The plasmid pJJ460 contains the CYC1 promoter, but
gives shorter transcript (250-270 nucleotides), and was added to
determine whether the factors associated with the immobilized template
could exchange onto a second promoter. Lane 1 shows a
positive control containing both immobilized and free templates
transcribed in wild-type whole cell extract (WCE).

View larger version (24K):
[in a new window]
Fig. 5.
TFIIB E62K is defective in single round
transcription. Transcription reactions under multiple (no
Sarkosyl) and single (0.1 and 0.3%) round initiation conditions were
carried out. Preinitiation complexes were formed by incubating template
for 20 min in wild-type (WT) or E62K extracts. The template
used in this experiment was p5×Gal4CG
, the same
construct as pGal4CG
, but carrying five copies of the
Gal4-binding site. NTPs were added to initiation reactions, and
Sarkosyl was added 1.5 min later to a final concentration of 0.1%
(lanes 3, 4, 9, and 10) or
0.3% (lanes 5, 6, 11, and
12). Reactions were further incubated for 10 min.
Transcription reactions were carried out both in the presence (+) and
absence (
) of the Gal4-VP16 activator. Transcripts were quantitated
by PhosphorImager, and relative levels are shown as numbers under each
lane.

View larger version (28K):
[in a new window]
Fig. 6.
Mammalian transcription of the adenovirus
major late promoter is not affected by mutation of glutamate 51 in
TFIIB. The human residue (Glu-51) corresponding to Glu-62 in yeast
was mutated to alanine or arginine. Transcription activity was tested
using a reconstituted mammalian transcription system and the adenovirus
major late promoter as template (pML
53(200) (38)). Each reaction
received no TFIIB (
; lane 1), human wild-type TFIIB
(hWT; lane 2), or mutant TFIIB with glutamate 51 changed to alanine (E51A) (lane 3) or arginine (E51R)
(lane 4).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Recipient of a Pew Scholar Award in the Biomedical Sciences and an
American Cancer Society Junior Faculty Research Award. To whom
correspondence should be addressed: Dept. of Biological Chemistry and
Molecular Pharmacology, 240 Longwood Av., Harvard Medical School,
Boston, MA 02115. Tel.: 617-432-0696; Fax: 617-738-0516; E-mail:
steveb@hms.harvard.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Buratowski, S.
(1994)
Cell
77,
1-3[CrossRef][Medline]
[Order article via Infotrieve]
2.
Orphanides, G.,
Lagrange, T.,
and Reinberg, D.
(1996)
Genes Dev.
10,
2657-2683 3.
Hampsey, M.
(1998)
Microbiol. Mol. Biol. Rev.
62,
465-503
4.
Nakajima, N.,
Horikoshi, M.,
and Roeder, R. G.
(1988)
Mol. Cell. Biol.
8,
4028-4040 5.
Buratowski, S.,
Hahn, S.,
Guarente, L.,
and Sharp, P. A.
(1989)
Cell
56,
549-561[CrossRef][Medline]
[Order article via Infotrieve]
6.
Corden, J.,
Wasylyk, B.,
Buchwalder, A.,
Sassone-Corsi, P.,
Kedinger, C.,
and Chambon, P.
(1980)
Science
209,
1406-1414 7.
Breathnach, R.,
and Chambon, P.
(1981)
Annu. Rev. Biochem.
50,
349-393[CrossRef][Medline]
[Order article via Infotrieve]
8.
Guarente, L.
(1987)
Annu. Rev. Genet.
21,
425-452[CrossRef][Medline]
[Order article via Infotrieve]
9.
Guarente, L.
(1988)
Cell
52,
303-305[CrossRef][Medline]
[Order article via Infotrieve]
10.
Struhl, K.
(1987)
Cell
49,
295-297[CrossRef][Medline]
[Order article via Infotrieve]
11.
Struhl, K.
(1989)
Annu. Rev. Biochem.
58,
1051-1077[CrossRef][Medline]
[Order article via Infotrieve]
12.
Winston, F.
(1992)
Transcriptional Regulation
, pp. 1271-1293, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
13.
Pinto, I.,
Ware, D. E.,
and Hampsey, M.
(1992)
Cell
68,
977-988[CrossRef][Medline]
[Order article via Infotrieve]
14.
Berroteran, R. W.,
Ware, D. E.,
and Hampsey, M.
(1994)
Mol. Cell. Biol.
14,
226-237 15.
Sun, Z.-W.,
Tessmer, A.,
and Hampsey, M.
(1996)
Nucleic Acids Res.
24,
2560-2566 16.
Furter-Graves, E. M.,
Hall, B. D.,
and Furter, R.
(1994)
Nucleic Acids Res.
22,
4932-4936 17.
Furter-Graves, E. M.,
Furter, R.,
and Hall, B. D.
(1991)
Mol. Cell. Biol.
11,
4121-4127 18.
Hull, M. W.,
McKune, K.,
and Woychik, N. A.
(1995)
Genes Dev.
9,
481-490 19.
Li, Y.,
Flanagan, P. M.,
Tschochner, H.,
and Kornberg, R. D.
(1994)
Science
263,
805-807 20.
Buratowski, S.,
and Zhou, H.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5633-5637 21.
Ha, I.,
Roberts, S.,
Maldonado, E.,
Sun, X.,
Kim, L.-U.,
Green, M.,
and Reinberg, D.
(1993)
Genes Dev.
7,
1021-1032 22.
Maldonado, E.,
Ha, I.,
Cortes, P.,
Weis, L.,
and Reinberg, D.
(1990)
Mol. Cell. Biol.
10,
6335-6347 23.
Barberis, A.,
Muller, C. W.,
Harrison, S. C.,
and Ptashne, M.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5628-5632 24.
Yamashita, S.,
Hisatake, K.,
Kokubo, T.,
Doi, K.,
Roeder, R. G.,
Horikoshi, M.,
and Nakatani, Y.
(1993)
Science
261,
463-466 25.
Bagby, S.,
Kim, S. J.,
Maldonado, E.,
Tong, K. I.,
Reinberg, D.,
and Ikura, M.
(1995)
Cell
82,
857-867[CrossRef][Medline]
[Order article via Infotrieve]
26.
Zhu, W. L.,
Zeng, Q. D.,
Colangelo, C. M.,
Lewis, L. M.,
Summers, M. F.,
and Scott, R. A.
(1996)
Nat. Struct. Biol.
3,
122-124[CrossRef][Medline]
[Order article via Infotrieve]
27.
Nikolov, D. B.,
Chen, H.,
Halay, E. D.,
Usheva, A. A.,
Hisatake, K.,
Lee, D. K.,
Roeder, R. G.,
and Burley, S. K.
(1995)
Nature
377,
119-128[CrossRef][Medline]
[Order article via Infotrieve]
28.
Pinto, I.,
Wu, W.-H.,
Na, J. G.,
and Hampsey, M.
(1994)
J. Biol. Chem.
269,
30569-30573 29.
Bangur, C. S.,
Pardee, T. S.,
and Ponticelli, A. S.
(1997)
Mol. Cell. Biol.
17,
6784-6793[Abstract]
30.
Cho, E.-J.,
Takagi, T.,
Moore, C. R.,
and Buratowski, S.
(1997)
Genes Dev.
11,
3319-3326 31.
Feaver, W. J.,
Henry, N. L.,
Bushnell, D. A.,
Sayre, M. H.,
Brickner, J. H.,
Gileadi, O.,
and Kornberg, R. D.
(1994)
J. Biol. Chem.
269,
27549-27553 32.
Thompson, N. E.,
Steinberg, T. H.,
Aronson, D. B.,
and Burgess, R. R.
(1989)
J. Biol. Chem.
264,
11511-11520 33.
Woontner, M.,
Wade, P. A.,
Bonner, J.,
and Jaehning, J. A.
(1991)
Mol. Cell. Biol.
11,
4555-4560 34.
Woontner, M.,
and Jaehning, J. A.
(1990)
J. Biol. Chem.
265,
8979-8982 35.
Lue, N. F.,
Flanagan, P. M.,
Sugimoto, K.,
and Kornberg, R. D.
(1989)
Science
246,
661-664 36.
Sawadogo, M.,
and Roeder, R. G.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
4394-4398 37.
Kim, Y.-J.,
Bjorklund, S.,
Li, Y.,
Sayre, M. H.,
and Kornberg, R. D.
(1994)
Cell
77,
599-608[CrossRef][Medline]
[Order article via Infotrieve]
38.
Buratowski, S.,
Hahn, S.,
Sharp, P. A.,
and Guarente, L.
(1988)
Nature
334,
37-42[CrossRef][Medline]
[Order article via Infotrieve]
39.
Parvin, J. D.,
and Sharp, P. A.
(1993)
Cell
73,
533-540[CrossRef][Medline]
[Order article via Infotrieve]
40.
Parvin, J. D.,
and Sharp, P. A.
(1991)
J. Biol. Chem.
266,
22878-22886 41.
White, J.,
Brou, C.,
Wu, J.,
Lutz, Y.,
Moncollin, V.,
and Chambon, P.
(1992)
EMBO J.
11,
2229-2240[Medline]
[Order article via Infotrieve]
42.
Shaw, S. P.,
Wingfield, J.,
Dorsey, M. J.,
and Ma, J.
(1996)
Mol. Cell. Biol.
16,
3651-3657[Abstract]
43.
Giardina, C.,
and Lis, J. T.
(1993)
Science
261,
759-761 44.
Leuther, K. K.,
Bushnell, D. A.,
and Kornberg, R. D.
(1996)
Cell
85,
773-779[CrossRef][Medline]
[Order article via Infotrieve]
45.
Wang, W.,
Carey, M.,
and Gralla, J. D.
(1992)
Science
255,
450-453 46.
Roberts, S. G. E.,
and Green, M. R.
(1994)
Nature
371,
717-720[CrossRef][Medline]
[Order article via Infotrieve]
47.
Knaus, R.,
Pollock, R.,
and Guarente, L.
(1996)
EMBO J.
15,
1933-1940[Medline]
[Order article via Infotrieve]
48.
Henry, N. L.,
Bushnell, D. A.,
and Kornberg, R. D.
(1996)
J. Biol. Chem.
271,
21842-21847 49.
Werten, S.,
Langen, F. W. M.,
Schaik, R. V.,
Timmers, H. T. M.,
Meisterernst, M.,
and van der Vliet, P. C.
(1998)
J. Mol. Biol.
276,
367-377[CrossRef][Medline]
[Order article via Infotrieve]
50.
Pardee, T. S.,
Bangur, C. S.,
and Ponticelli, A. S.
(1998)
J. Biol. Chem.
273,
17859-17864 51.
Ranish, J. A.,
Yudkovsky, N.,
and Hahn, S.
(1999)
Genes Dev.
13,
49-63 52.
Kassavetis, G. A.,
Kumar, A.,
Letts, G. A.,
and Geiduschek, E.-P.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9196-9201 53.
Hawkes, N.,
and Roberts, S. G. E.
(1999)
J. Biol. Chem.
274,
14337-14343
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H. J. Baek, Y. K. Kang, and R. G. Roeder Human Mediator Enhances Basal Transcription by Facilitating Recruitment of Transcription Factor IIB during Preinitiation Complex Assembly J. Biol. Chem., June 2, 2006; 281(22): 15172 - 15181. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Freire-Picos, S. Krishnamurthy, Z.-W. Sun, and M. Hampsey Evidence that the Tfg1/Tfg2 dimer interface of TFIIF lies near the active center of the RNA polymerase II initiation complex Nucleic Acids Res., September 7, 2005; 33(16): 5045 - 5052. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-S. Chen and M. Hampsey Functional Interaction between TFIIB and the Rpb2 Subunit of RNA Polymerase II: Implications for the Mechanism of Transcription Initiation Mol. Cell. Biol., May 1, 2004; 24(9): 3983 - 3991. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Glossop, T. R. Dafforn, and S. G. E. Roberts A conformational change in TFIIB is required for activator-mediated assembly of the preinitiation complex Nucleic Acids Res., March 22, 2004; 32(5): 1829 - 1835. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Bushnell, K. D. Westover, R. E. Davis, and R. D. Kornberg Structural Basis of Transcription: An RNA Polymerase II-TFIIB Cocrystal at 4.5 Angstroms Science, February 13, 2004; 303(5660): 983 - 988. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Bartlett, M. Thomm, and E. P. Geiduschek Topography of the Euryarchaeal Transcription Initiation Complex J. Biol. Chem., February 13, 2004; 279(7): 5894 - 5903. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Renfrow, N. Naryshkin, L. M. Lewis, H.-T. Chen, R. H. Ebright, and R. A. Scott Transcription Factor B Contacts Promoter DNA Near the Transcription Start Site of the Archaeal Transcription Initiation Complex J. Biol. Chem., January 23, 2004; 279(4): 2825 - 2831. |